Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $5.6250 (8.17%) ($5.6250 - $5.6250) on Tue. Jul. 12, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.52% (three month average) | RSI | 70 | Latest Price | $5.6250(8.17%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 1.5% a day on average for past five trading days. | Weekly Trend | TGTX advances 12.3% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(78%) ARKG(75%) ARKK(68%) IBB(68%) XLC(63%) | Factors Impacting TGTX price | TGTX will decline at least -3.76% in a week (0% probabilities). UUP(-23%) TBT(-21%) USO(-16%) XLE(-9%) OIH(-8%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.76% (StdDev 7.52%) | Hourly BBV | 1.1 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $5.45(3.21%) | 10 Day Moving Average | $5(12.5%) | 20 Day Moving Average | $4.6(22.28%) | To recent high | -42% | To recent low | 50.6% | Market Cap | $712m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |